{"title":"多血管疾病急性冠状动脉综合征患者血管重建完整性和高出血风险状态的影响:回顾性分析","authors":"Tanawat Attachaipanich, Phasakorn Putchagarn, Tasalak Thonghong, Krit Leemasawat, Panupong Pota, Aekapat Phoksiri, Srun Kuanprasert, Pannipa Suwannasom","doi":"10.1177/20480040241283152","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the long-term mortality of acute coronary syndrome (ACS) patients with multivessel disease according to the level of completeness of revascularization (CR) and high-bleeding risk (HBR) status.</p><p><strong>Design setting and participants: </strong>This retrospective study collected the data of ACS patients with multivessel disease who underwent percutaneous coronary intervention between May 2018 and February 2019. Complete to reasonable revascularization (CR) was defined by the residual Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score (RSS) of 0 to ≤8. The HBR was defined by the PRECISE-DAPT score ≥25.</p><p><strong>Main outcome measures: </strong>The all-cause death at 36 months according to the CR and HBR status.</p><p><strong>Results: </strong>A total of 209 patients with 743 lesions were included in the analysis. The median follow-up was 3.6 years. Patients with CR had lower event rates than ICR (4.5 vs. 11.5 per 100 patient-year, HR 0.39, 95% CI 0.22-0.70), p = 0.002). Similar observations were noted when compared between non-HBR and HBR (3.9 vs. 11.1 per 100 patient-year, HR 0.35, 95% CI 0.18-0.64, p < 0.001). Kaplan-Meier analysis revealed that all-cause death was highest among those in the ICR/HBR (40.5%) followed by ICR/non-HBR (28.6%), CR/non-HBR (28.3%) and the lowest among the CR/HBR group (7.1%), log-rank p = <0.001. No significant interaction was observed between the two factors regarding all-cause death (p = 0.10 for interaction).</p><p><strong>Conclusions: </strong>In ACS patients with MVD, the achievement of CR was associated with reducing mortality rates and consistency irrespective of the HBR status. (Trial Registration: TCTR20211222003).</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"13 ","pages":"20480040241283152"},"PeriodicalIF":1.4000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437547/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis.\",\"authors\":\"Tanawat Attachaipanich, Phasakorn Putchagarn, Tasalak Thonghong, Krit Leemasawat, Panupong Pota, Aekapat Phoksiri, Srun Kuanprasert, Pannipa Suwannasom\",\"doi\":\"10.1177/20480040241283152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the long-term mortality of acute coronary syndrome (ACS) patients with multivessel disease according to the level of completeness of revascularization (CR) and high-bleeding risk (HBR) status.</p><p><strong>Design setting and participants: </strong>This retrospective study collected the data of ACS patients with multivessel disease who underwent percutaneous coronary intervention between May 2018 and February 2019. Complete to reasonable revascularization (CR) was defined by the residual Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score (RSS) of 0 to ≤8. The HBR was defined by the PRECISE-DAPT score ≥25.</p><p><strong>Main outcome measures: </strong>The all-cause death at 36 months according to the CR and HBR status.</p><p><strong>Results: </strong>A total of 209 patients with 743 lesions were included in the analysis. The median follow-up was 3.6 years. Patients with CR had lower event rates than ICR (4.5 vs. 11.5 per 100 patient-year, HR 0.39, 95% CI 0.22-0.70), p = 0.002). Similar observations were noted when compared between non-HBR and HBR (3.9 vs. 11.1 per 100 patient-year, HR 0.35, 95% CI 0.18-0.64, p < 0.001). Kaplan-Meier analysis revealed that all-cause death was highest among those in the ICR/HBR (40.5%) followed by ICR/non-HBR (28.6%), CR/non-HBR (28.3%) and the lowest among the CR/HBR group (7.1%), log-rank p = <0.001. No significant interaction was observed between the two factors regarding all-cause death (p = 0.10 for interaction).</p><p><strong>Conclusions: </strong>In ACS patients with MVD, the achievement of CR was associated with reducing mortality rates and consistency irrespective of the HBR status. (Trial Registration: TCTR20211222003).</p>\",\"PeriodicalId\":30457,\"journal\":{\"name\":\"JRSM Cardiovascular Disease\",\"volume\":\"13 \",\"pages\":\"20480040241283152\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437547/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JRSM Cardiovascular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20480040241283152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JRSM Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20480040241283152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的根据血管再通(CR)完全程度和高出血风险(HBR)状态,研究急性冠状动脉综合征(ACS)多支血管疾病患者的长期死亡率:这项回顾性研究收集了2018年5月至2019年2月期间接受经皮冠状动脉介入治疗的多支血管疾病ACS患者的数据。完全至合理血运重建(CR)的定义是:Taxus经皮冠状动脉介入治疗与心脏手术之间的剩余协同作用评分(RSS)为0至≤8。HBR的定义是PRECISE-DAPT评分≥25分:主要结果指标:根据CR和HBR状态得出的36个月内全因死亡人数:共有209名患者的743个病灶被纳入分析。中位随访时间为3.6年。CR患者的事件发生率低于ICR患者(4.5 vs. 11.5 per 100 patient-year, HR 0.39, 95% CI 0.22-0.70), p = 0.002)。非 HBR 和 HBR 相比也有类似的观察结果(每 100 名患者每年 3.9 例与 11.1 例相比,HR 0.35,95% CI 0.18-0.64,P=0.002):在患有 MVD 的 ACS 患者中,无论 HBR 状态如何,达到 CR 都与降低死亡率和一致性相关。(试验注册:TCTR20211222003)。
Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis.
Objectives: To investigate the long-term mortality of acute coronary syndrome (ACS) patients with multivessel disease according to the level of completeness of revascularization (CR) and high-bleeding risk (HBR) status.
Design setting and participants: This retrospective study collected the data of ACS patients with multivessel disease who underwent percutaneous coronary intervention between May 2018 and February 2019. Complete to reasonable revascularization (CR) was defined by the residual Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score (RSS) of 0 to ≤8. The HBR was defined by the PRECISE-DAPT score ≥25.
Main outcome measures: The all-cause death at 36 months according to the CR and HBR status.
Results: A total of 209 patients with 743 lesions were included in the analysis. The median follow-up was 3.6 years. Patients with CR had lower event rates than ICR (4.5 vs. 11.5 per 100 patient-year, HR 0.39, 95% CI 0.22-0.70), p = 0.002). Similar observations were noted when compared between non-HBR and HBR (3.9 vs. 11.1 per 100 patient-year, HR 0.35, 95% CI 0.18-0.64, p < 0.001). Kaplan-Meier analysis revealed that all-cause death was highest among those in the ICR/HBR (40.5%) followed by ICR/non-HBR (28.6%), CR/non-HBR (28.3%) and the lowest among the CR/HBR group (7.1%), log-rank p = <0.001. No significant interaction was observed between the two factors regarding all-cause death (p = 0.10 for interaction).
Conclusions: In ACS patients with MVD, the achievement of CR was associated with reducing mortality rates and consistency irrespective of the HBR status. (Trial Registration: TCTR20211222003).